- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05995353
Une étude pour évaluer les événements indésirables, les changements dans l'activité de la maladie et la façon dont le risankizumab intraveineux et sous-cutané se déplace dans le corps des participants pédiatriques atteints de la maladie de Crohn active de modérément à sévèrement (RISE)
Une étude multicentrique de phase 3 pour évaluer la pharmacocinétique, l'efficacité et l'innocuité du risankizumab avec induction en ouvert, entretien randomisé en double aveugle et périodes d'extension à long terme chez des sujets pédiatriques (âgés de 2 à < 18 ans) avec Maladie de Crohn modérément à sévèrement active
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: ABBVIE CALL CENTER
- Numéro de téléphone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lieux d'étude
-
-
Bavaria
-
Munich, Bavaria, Allemagne, 80337
- Recrutement
- Dr. von Haunerschen Kinderspital /ID# 255577
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Allemagne, 48149
- Recrutement
- Universitaetsklinikum Muenster /ID# 256762
-
-
-
-
-
Brussels, Belgique, 1020
- Recrutement
- Hospital Universite Enfants Reine Fabiola /ID# 255112
-
Liège, Belgique, 4000
- Recrutement
- Groupe Sante CHC - Clinique du MontLegia /ID# 255620
-
-
Antwerpen
-
Edegem, Antwerpen, Belgique, 2650
- Recrutement
- Uza /Id# 255114
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgique, 1200
- Recrutement
- Cliniques Universitaires UCL Saint-Luc /ID# 255108
-
Jette, Brussels Capital, Belgique, 1090
- Recrutement
- Universitair Ziekenhuis Brussel /ID# 255109
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgique, 3000
- Recrutement
- Universitair Ziekenhuis Leuven /ID# 255098
-
-
-
-
-
Plovdiv, Bulgarie, 4002
- Recrutement
- UMHAT Sveti Georgi EAD /ID# 255386
-
Sofia, Bulgarie, 1606
- Complété
- Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
-
Varna, Bulgarie, 9009
- Recrutement
- UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Recrutement
- Alberta Children's Hospital /ID# 255357
-
Edmonton, Alberta, Canada, T6G 1C9
- Recrutement
- Edmonton Clinic Health Academy /ID# 255361
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Recrutement
- BC Children's Hospital /ID# 255359
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Recrutement
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100045
- Recrutement
- Beijing Children's Hospital /ID# 256081
-
Beijing, Beijing Municipality, Chine, 100191
- Recrutement
- Peking University Third Hospital /ID# 255876
-
Contact:
- Site Coordinator
- Numéro de téléphone: +86 010-82266699
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510620
- Recrutement
- Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
-
Guangzhou, Guangdong, Chine, 510655
- Recrutement
- The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
-
-
Henan
-
Zhengzhou, Henan, Chine, 450018
- Recrutement
- Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
-
-
Hunan
-
Changsha, Hunan, Chine, 410007
- Recrutement
- Hunan Children's Hospital /ID# 255610
-
-
Jiangxi
-
Nanchang, Jiangxi, Chine, 330006
- Recrutement
- Jiangxi Provincial Children's Hospital /ID# 255564
-
-
Liaoning
-
Shenyang, Liaoning, Chine, 110022
- Recrutement
- Shengjing Hospital of China Medical University /ID# 255563
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200062
- Recrutement
- Children's Hospital of Shanghai /ID# 255531
-
Shanghai, Shanghai Municipality, Chine, 200065
- Recrutement
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
-
-
-
-
-
Daegu, Corée du Sud, 41404
- Recrutement
- Kyungpook National University Chilgok Hospital /ID# 255817
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Corée du Sud, 03080
- Recrutement
- Seoul National University Hospital /ID# 255318
-
Seoul, Seoul Teugbyeolsi, Corée du Sud, 06351
- Recrutement
- Samsung Medical Center /ID# 255284
-
Seoul, Seoul Teugbyeolsi, Corée du Sud, 03722
- Recrutement
- Yonsei University Health System - Severance Hospital /ID# 256976
-
-
-
-
-
Madrid, Espagne, 28009
- Complété
- Hospital Infantil Universitario Nino Jesus /ID# 255012
-
Málaga, Espagne, 29011
- Recrutement
- Hospital Regional Universitario de Malaga /ID# 257553
-
-
A Coruna
-
Ferrol, A Coruna, Espagne, 15405
- Recrutement
- Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
-
-
-
-
-
Paris, France, 75015
- Recrutement
- AP-HP - Hopital Necker /ID# 255608
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, France, 37044
- Recrutement
- CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, France, 33076
- Recrutement
- Chu Bordeaux - Hopital Pellegrin /ID# 257060
-
-
Occitanie
-
Toulouse, Occitanie, France, 31059
- Recrutement
- CHU Toulouse - Hopital Paule de Viguier /ID# 255609
-
-
Rhone
-
Bron, Rhone, France, 69500
- Recrutement
- Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
-
-
-
-
Central District
-
Petah Tikva, Central District, Israël, 4920235
- Recrutement
- Schneider Children's Medical Center /ID# 254950
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israël, 91031
- Recrutement
- Shaare Zedek Medical Center /ID# 254951
-
-
-
-
-
Messina, Italie, 98125
- Recrutement
- Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
-
-
Genova
-
Genoa, Genova, Italie, 16147
- Recrutement
- IRCCS Istituto Giannina Gaslini /ID# 255262
-
-
Napoli
-
Naples, Napoli, Italie, 80131
- Recrutement
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
-
-
Roma
-
Rome, Roma, Italie, 00165
- Recrutement
- Ospedale Pediatrico Bambino Gesu /ID# 255043
-
-
-
-
Aichi-ken
-
Ōbu, Aichi-ken, Japon, 474-8710
- Recrutement
- Aichi Children's Health And Medical Center /ID# 272085
-
-
Chiba
-
Kashiwa-shi, Chiba, Japon, 277-0871
- Recrutement
- Tsujinaka Hospital - Kashiwanoha /ID# 268409
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Japon, 830-0011
- Recrutement
- Kurume University Hospital /ID# 268418
-
-
Gunma
-
Maebashi, Gunma, Japon, 371-8511
- Recrutement
- Gunma University Hospital /ID# 270560
-
-
Kumamoto
-
Kumamoto, Kumamoto, Japon, 861-8520
- Recrutement
- Japanese Red Cross Kumamoto Hospital /ID# 268586
-
-
Osaka
-
Izumi-Shi, Osaka, Japon, 594-1101
- Recrutement
- Osaka Women's and Children's Hospital /ID# 268419
-
-
Saitama
-
Saitama-shi, Saitama, Japon, 330-8777
- Recrutement
- Saitama Children's Medical Center /ID# 268410
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japon, 113-8519
- Recrutement
- Institute of Science Tokyo Hospital /ID# 269175
-
Fuchu-shi, Tokyo, Japon, 183-8561
- Recrutement
- Tokyo Metropolitan Children's Medical Center /ID# 268415
-
Setagaya City, Tokyo, Japon, 157-8535
- Recrutement
- National Center For Child Health And Development /ID# 268420
-
-
-
-
North Holland
-
Amsterdam, North Holland, Pays-Bas, 1105 AZ
- Recrutement
- Amsterdam University Medical Center /ID# 254827
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Torun, Kuyavian-Pomeranian Voivodeship, Pologne, 87-100
- Complété
- Gastromed Sp. z o.o /ID# 255939
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Pologne, 04-730
- Recrutement
- Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
-
-
-
-
-
Dorado, Porto Rico, 00646
- Recrutement
- Puerto Rico Health Institute /ID# 255071
-
San Juan, Porto Rico, 00909-1711
- Recrutement
- Clinical Research Puerto Rico /ID# 266479
-
-
-
-
-
Birmingham, Royaume-Uni, B4 6NH
- Recrutement
- Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
-
-
England
-
Sheffield, England, Royaume-Uni, S10 2TH
- Recrutement
- Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
-
Contact:
- Site Coordinator
- Numéro de téléphone: +44 114 273 0522
-
-
Greater London
-
London, Greater London, Royaume-Uni, E1 2ES
- Recrutement
- Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
-
-
-
-
-
Bern, Suisse, 3010
- Recrutement
- Inselspital, Universitaetsspital Bern /ID# 255321
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Suisse, 8032
- Recrutement
- Kinderspital Zurich - Eleonorenstiftung /ID# 255337
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Suède, 118 83
- Recrutement
- Sodersjukhuset /ID# 255239
-
Stockholm, Stockholm County, Suède, 171 76
- Recrutement
- Astrid Lindgrens Barnsjukhus /ID# 255240
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Suède, 413 46
- Recrutement
- Sahlgrenska Universitetssjukhuset /ID# 255236
-
Contact:
- Site Coordinator
- Numéro de téléphone: +46313435865
-
-
-
-
-
Changhua City, Changhua County, Taïwan, 50006
- Recrutement
- Changhua Christian Hospital /ID# 256082
-
Taipei, Taïwan, 100
- Recrutement
- National Taiwan University Hospital /ID# 255679
-
-
-
-
Praha 17
-
Prague, Praha 17, Tchéquie, 128 00
- Complété
- Vseobecna Fakultni nemocnice v Praze /ID# 256096
-
-
Praha 5
-
Prague, Praha 5, Tchéquie, 150 06
- Complété
- Fakultni nemocnice Motol a Homolka /ID# 256547
-
-
-
-
-
Ankara, Turquie (Türkiye), 06560
- Recrutement
- Gazi University Medical Faculty /ID# 255086
-
Istanbul, Turquie (Türkiye), 34453
- Recrutement
- Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
-
Istanbul, Turquie (Türkiye), 34899
- Recrutement
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
-
Kocaeli, Turquie (Türkiye), 41380
- Recrutement
- Kocaeli University Med Faculty /ID# 256922
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85016-7710
- Recrutement
- Phoenix Children's Hospital /ID# 255766
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72202
- Complété
- Arkansas Children's Hospital /ID# 255762
-
-
California
-
Oakland, California, États-Unis, 94609
- Recrutement
- UCSF Benioff Children's Hospital - Oakland /ID# 258327
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- Children's Hospital Colorado - Aurora /ID# 255764
-
-
Florida
-
Orlando, Florida, États-Unis, 32806-1141
- Recrutement
- Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Indiana University Health Riley Hospital for Children /ID# 256454
-
-
Massachusetts
-
Waltham, Massachusetts, États-Unis, 02451
- Recrutement
- Massachusetts General Hospital - Mass General Waltham /ID# 255767
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55413-2195
- Recrutement
- MNGI Digestive Health, P. A. /ID# 255366
-
-
New Jersey
-
Morristown, New Jersey, États-Unis, 07960
- Recrutement
- Goryeb Childrens Hospital /ID# 256452
-
-
New York
-
New York, New York, États-Unis, 10029
- Recrutement
- Icahn School of Medicine at Mount Sinai /ID# 254880
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Recrutement
- Cleveland Clinic - Cleveland /ID# 256453
-
Contact:
- Site Coordinator
- Numéro de téléphone: 216-636-2007
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Pediatric individuals, 2 to < 18 years old
- Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
- Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
- Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Exclusion Criteria:
-
History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
-
Any of the following medical disorders:
-
Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
-
A diagnosis of CD prior to 2 years of age.
-
A diagnosis or suspected diagnosis of a primary immunodeficiency.
-
Currently known complications of CD such as:
- Active abscess (abdominal or perianal);
- Symptomatic bowel strictures;
- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
- Fulminant colitis;
- Toxic megacolon;
- Or any other manifestation that might require surgery while enrolled in the study.
-
Ostomy or ileoanal pouch.
-
Diagnosis of short gut or short bowel syndrome.
-
Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.
-
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PK Cohort 1: SS3 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 1: SS3 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 1: SS1
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 1: SS2 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 1: SS2 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
|
Expérimental: Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Autres noms:
Subcutaneous (SC) Injection
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Délai: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Délai: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Délai: Up to approximately Week 64
|
Cmax of risankizumab |
Up to approximately Week 64
|
|
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Délai: Up to approximately 64 weeks
|
Tmax of risankizumab |
Up to approximately 64 weeks
|
|
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Délai: Up to approximately 64 weeks
|
AUCtau of risankizumab |
Up to approximately 64 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Délai: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Délai: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Délai: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Délai: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Délai: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Délai: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Délai: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Délai: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Délai: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Délai: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Délai: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Délai: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: ABBVIE INC., AbbVie
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- M16-194
- 2022-502050-14-00 (Autre identifiant: EU CT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Délai de partage IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Critères d'accès au partage IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .